openPR Logo
Press release

Leukemia Therapeutics Market – Global Industry Insights, 2025

09-22-2017 05:21 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Leukemia Therapeutics Market – Global Industry Insights,

Leukemia is a cancer of blood cells and therefore, are occasionally referred to as ‘blood cancer’. Most blood cells are formed in the bone marrow. In leukemia, undeveloped blood cells become cancer. Leukemia can be either acute or chronic. Acute leukemia is a fast growing cancer, which usually gets worse rapidly. Chronic leukemia is a slow growing cancer, which gets worse slowly over time period. The treatment and diagnosis of leukemia depends on the type of blood cell affected and whether the leukemia is chronic or acute. Every day, billions of new blood cells are produced in the bone marrow most of them red cells. However, leukemia leads to abnormally high production of white cells. These leukemia cells cannot fight infection the way normal white blood cells do, and in time adversely affect the way major organs function. Eventually, there this not enough red blood cells to supply oxygen, enough platelets to clot the blood, or enough normal white blood cells to fight infection.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/528

According to Center for Disease Control and Prevention (CDC), in the U. S. in 2013, 45,360 people were diagnosed with leukemia, leading to 23,549 fatalities (13,625 men and 9,924 women). Leukemia is frequently considered as a children’s condition, though it mainly affects adults. The condition is more prevalent among men than women, and more in Caucasians than African Americans.

Leukemia Therapeutics Market

On the basis of disease condition, the global leukemia therapeutics market is classified into:

Acute lymphocytic leukemia
Chronic lymphocytic leukemia
Acute myeloid leukemia
Chronic myeloid leukemia
On the basis of treatment, the global leukemia therapeutics market is classified into:

Immunotherapy
Targeted Therapy
Bone Marrow Transplant
Stem Cell Therapy
High diagnosis rate in developed economies supporting the leukemia therapeutics market growth in those regions

According to the Centre for Disease Control (CDC), around 14.1 million people were diagnosed with cancer in 2012, resulting in around 8.2 million fatalities. Around 19.3 million new cases of cancer are projected to be diagnosed by 2025. Leukemia cases are projected to be more in the developed world regions such as North America and Europe, owing to genetic factors caused by enhanced radiation exposure. Environmental factors and unhealthy lifestyles are the factors which add to the count. There are about 54,270 new cases of leukemia in the U. S. each year. Leukemia makes up about 3% of all new cancer cases. According to the World Cancer Research Fund, stated that up to one third of the cancer cases which occur in economically developed countries such as the US, and Europe owing to lack of physical activity, overweight (obesity), and/or poor nutrition. Additionally, the demand for effective and safe treatment is gaining prevalence in the market. Around 90% of the leukemia occur in the middle age and develops with the aging. Thus, leukemia therapeutics market is composed to grow with the rise in aging population and increasing incidences of leukemia.

Similarly, in emerging economies of Asia Pacific such as China, and India, the leukemia therapeutics market is expected to grow promptly due to presence of high unmet needs. However, low diagnosis rate of leukemia and lack of proper healthcare facilities in few Asian and African countries is deterring the leukemia therapeutics market growth in these regions.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/leukemia-therapeutics-market-528

Key players operating in the global leukemia therapeutics market are GSK, Eisai C., Pfizer, Biogen, Celgene, Novartis AG, Genzyme Corporation, Roche, and Bristol Myers Squibb Company (BMS). Companies are following new growth strategies such as product launch, product pipeline, merger & acquisitions, clinical trials and collaboration & agreements, to gain competitive advantage. For example, Novartis recently launched tyrosine kinase receptor FLT-3 for the treatment of leukemia. Pfizer implemented product expansion strategy to capture major market share, received Food and Drug Approval (FDA) for its Bosulif drug.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leukemia Therapeutics Market – Global Industry Insights, 2025 here

News-ID: 735413 • Views: 512

More Releases from Coherent Market Insights

Neuropathic pain Market is Going to Boom With Pfizer, Sanofi S.A., GlaxoSmithKli …
Neuropathic pain is caused by damage or disease to the central nervous system, which causes the pain pathways in the body to malfunction. Muscle, fascia, tendons, and ligaments can be severely damaged, resulting in necrosis or atrophy. Neuropathic pain is caused by neuromuscular disorders such as diabetes, Parkinson's disease, spinal injuries, and rheumatoid arthritis. Neuropathic pain can manifest itself in any part of the body, causing excruciating agony, persistent weariness,
Oncology Drugs Market is Going to Boom With Hoffmann-La Roche AG, Novartis Inter …
𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 has recently genuine information on the "Oncology Drugs Market" to its database. This research paper examines several viewpoints from the inside out, such as market patterns, elements of the entire industry, drivers, restraints, and opportunities. It provides an investigative perspective to help organizations make more informed decisions. It contains in-depth information on a variety of prominent players from around the world. Oncology Drugs Market reports spread a total
Back Pain Therapy Market Industry Insights, Trends, Outlook, and Analysis by 202 …
𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 has recently genuine information on the "Back Pain Therapy Market" to its database. This research paper examines several viewpoints from the inside out, such as market patterns, elements of the entire industry, drivers, restraints, and opportunities. It provides an investigative perspective to help organizations make more informed decisions. It contains in-depth information on a variety of prominent players from around the world. Back Pain Therapy Market reports spread
Equine Healthcare Market Is Growing Rapidly with Affymetrix, Boehringer Ingelhei …
𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 has recently genuine information on the "Equine Healthcare Market" to its database. This research paper examines several viewpoints from the inside out, such as market patterns, elements of the entire industry, drivers, restraints, and opportunities. It provides an investigative perspective to help organizations make more informed decisions. It contains in-depth information on a variety of prominent players from around the world. Equine Healthcare Market reports spread a total

All 5 Releases


More Releases for Leukemia

Global Leukemia Therapeutics Market Continued Growth Report
The “Global Leukemia Therapeutics Market Continued Growth Report” Latest added Leukemia Therapeutics Market research study by Zion Market Research offers detailed product outlook and elaborates market review till 2026. , The Leukemia Therapeutics Market is the most blooming and promising sector of the industry. This overall Leukemia Therapeutics Market has been ascending at a higher rate with the enhancement of inventive strategies and a raising customer tendency. The wide-coming to
Juvenile Myelomonocytic Leukemia Therapeutics- Pipeline Analysis 2018
Juvenile myelomonocytic leukemia is a rare disease that occurs mostly in the children who are under four years of age. The abnormal growth of the monocytes results in the accumulation of monocytes in the bone marrow. Download the sample report @ https://www.pharmaproff.com/request-sample/1116 This leads to improper functioning of the bone marrow. The actual cause of juvenile myelomonocytic leukemia is still unknown; however, mutation in the RAS gene is observed in patients
Acute Myeloid Leukemia Market Growth by 2021
Acute Myeloid Leukemia (AML) is classed as an orphans disease. AML is a rare but a severe disease and is a most common leukemia. It is primarily a disease of the elderly, with an average age of diagnosis of approximately 66. AML results from the acquired changes in the DNA of a developing marrow cell. The marrow cells get converted into the leukemic cells, multiplies into 11 billion or more.
Acute Leukemia Therapeutics Pipeline Analysis
Acute leukemia is also known as cancer of blood cells in which immature blood cells modify into cancer cells. The disease arises from bone marrow and causes formation of numerous large blood cells. Leukemia is categorized into five different types namely acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and hairy cell leukemia. Leukemia can produce be symptoms such as fever, recurrent nosebleeds, bone pain, swollen
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo several stressful therapeutic interventions. If chemotherapy is not effective, stem cell transplantation mostly is the last chance for healing. However, a sudden graft rejection or disease relapse can always occur despite the successful transfer of the hematopoietic stem cells from donor to recipient. Therefore, the regular quantitative assessment of the donor and recipient cell-portion in the blood
Acute Myeloid Leukemia - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Acute Myeloid Leukemia - Heat Map and Analysis to its growing collection of premium market research reports. Acute Myeloid Leukemia (AML) is a rare but serious disease, and the most common leukemia suffered by adults. The first-line treatment in eligible patients is almost always intensive chemotherapy. Despite strong initial remission rates, relapse is common, and AML has the lowest five-year